Osamu Takeyama, Iwao Ikai, Toshikazu Yagi, Seiji Satoh, Akiyoshi Kanazawa, Takehiko Uesugi, Ryuta Nishitai, Hiroshi Okabe, Nagato Katsura, Hiroaki Terajima, Yoshio Yamaoka – 30 December 2003 – Xenogeneic extracorporeal liver perfusion (ECLP) has the potential to become an important tool in the management of patients with severe liver failure. We previously showed that xenogeneic pig liver perfusion may be prolonged for up to 9 hours by the administration of prostaglandin E1 (PGE1).

Ashok Jain, Anthony Jake Demetris, Randeep Kashyap, Karen Blakomer, Kris Ruppert, Akhtar Khan, Susan Rohal, Thomas E. Starzl, John J. Fung – 30 December 2003 – Tacrolimus has proven to be a potent immunosuppressive agent in liver transplantation (LT). Its introduction has led to significantly less frequent and severe acute rejection. Little is known about the rate of chronic rejection (CR) in primary LT using tacrolimus therapy. The aim of the present study is to examine the long‐term incidence of CR, risk factors, prognostic factors, and outcome after CR.

J. Diego Bogetti, Brian R. Herts, Mark J. Sands, John F. Carroll, David P. Vogt, J. Michael Henderson – 30 December 2003 – Three‐dimensional (3D) computed tomography (CT) is an imaging technique that renders anatomic detail in 3D images from helical computed tomographic scans. The purpose of this study is to assess 3D CT in the preoperative evaluation of adult living related liver transplant donors. Nine patients underwent right‐lobe liver resection for adult living related liver transplants between October 1999 and September 2000.

Thiagarajan Ramcharan, Brooke Glessing, John R. Lake, William D. Payne, Abhinav Humar – 30 December 2003 – Split‐liver transplantation is becoming a useful technique to expand the donor pool. Whether the split should be performed in situ or ex situ is not clear. One potential disadvantage of in situ splits is that prolonged surgical time and increased blood loss may negatively affect the function of other solid organs (kidneys, pancreas, and heart) procured from the same donor. Therefore, we studied the function of other organs posttransplantation.

Juan Figueras, Laura Llado, Emilio Ramos, Eduardo Jaurrieta, Antonio Rafecas, Juan Fabregat, Jaume Torras, Antonio Sabate, Antonia Dalmau – 30 December 2003 – This study aims to determine whether the use of a temporary portocaval shunt (PCS) improves hemodynamic and metabolic evolution during orthotopic liver transplantation (OLT). Preservation of the vena cava during OLT has gained wide acceptance. However, benefits of adding a temporary PCS to the piggyback technique during the anhepatic phase in patients with cirrhosis have not been shown.

Daniel Seehofer, Nada Rayes, Thomas Steinmüller, Andrea R. Müller, Utz Settmacher, Ruth Neuhaus, Cornelia Radke, Thomas Berg, Uwe Hopf, Peter Neuhaus – 30 December 2003 – Lamivudine treatment of hepatitis B after orthotopic liver transplantation (OLT) is often accompanied by fast viral‐resistance formation. Although no clinical data are available, in vitro data indicate that lamivudine‐resistant reinfection has a mild course because of defective viral replication. Between 1996 and 1999, a total of 34 patients were treated with lamivudine because of hepatitis B recurrence after OLT.

Sue V. McDiarmid – 30 December 2003 – Key Points 1In pretransplant management, the prevention and treatment of malnutrition is essential for pediatric patients as malnutrition is associated with both increased pre‐ and posttransplant mortality.2Technical complications, particularly hepatic artery thrombosis, after pediatric liver transplantation are relatively common given the small size of the majority of the recipients.

Gregory J. Gores – 30 December 2003 – Objectives: The prevalence of hepatocellular carcinoma (HCC) in primary biliary cirrhosis (PBC) is not well established, as some reports suggest a low risk, whereas others indicate that HCC may be no less frequent than in other types of cirrhosis. Methods: We compared the incidence of HCC in a series of 140 patients with PBC (five men, 135 women, mean age 54 ± 1.6 yr) followed‐up for a mean of period of 5.6 ± 0.4 yr with a group of patients with cirrhosis related to hepatitis C virus (HCV) who were matched for age, sex, and follow‐up period.

Yasuhiko Sugawara, Masatoshi Makuuchi, Junichi Kaneko, Takao Ohkubo, Yuichi Matsui, Hiroshi Imamura – 30 December 2003 – A new technique is reported for complete venous drainage for a left liver with caudate lobe graft when a short hepatic vein and left and middle hepatic veins are located close to each other.

Cathal O'Keeffe, Alan W. Baird, Niamh Nolan, P. Aiden McCormick – 30 December 2003 – The pathogenesis of chronic hepatic allograft rejection is poorly understood. Recent studies suggested that hepatic mast cells may be involved in the pathogenesis of chronic cholestatic liver disease. Because chronic rejection after liver transplantation is predominantly a cholestatic process, the aim of this study is to determine whether hepatic mast cells are involved in its pathogenesis.